However, lung cancer patients with a single copy of the variant allele (GT) for the MSH6 557G > T polymorphism who received docetaxel along with first-line chemotherapy had a poorer median survival time compared to those with the TT genotype receiving the same regimen (MST = 4.9 vs 9.13, Log-rank p = 0.02). This evidence concerns the gene MSH6 and lung cancer.